Fresenius Keeps Sara Hennicken’s in CFO Tenure Amid Strategic Evolution

Fresenius, a global healthcare enterprise, has announced the extension of Sara Hennicken’s tenure as Chief Financial Officer (CFO) until 2027, originally scheduled to conclude in 2025.

Assuming the CFO role in 2022, succeeding Rachel Empey, Hennicken has been instrumental in spearheading the company’s #FutureFresenius strategy. This strategic initiative has entailed streamlining governance and group structure while overseeing the deconsolidation of Fresenius Medical Care in 2023, with Fresenius retaining its position as the principal shareholder of Fresenius Medical Care.

Under the ambit of the #FutureFresenius strategy, Fresenius has directed its focus towards its operating entities, Fresenius Kabi and Fresenius Helios. These business segments command leading positions in what the company identifies as lucrative growth markets. Emphasizing (Bio)Pharma, MedTech, and Care Provision, they represent three pivotal growth platforms within the therapy sector, as outlined by the company.

Have you read?
Revealed: Countries With the Highest (and Lowest) Suicide Rates, 2024.
Revealed: Countries with the Highest Fertility Rates (by Births Per Woman), 2024.
Revealed: Countries with the most vegetarians in the world, 2024.
Revealed: The best countries in the world for expat retirement, 2024.
Ranked: The Most and Least Developed Countries in the World, 2024.